The START Center for Cancer Research (START) has entered a partnership with Trialing, aimed at increasing oncology clinical trial access across Europe.

The collaboration seeks to facilitate connections between physicians and active clinical trials, optimising the referral process and expanding opportunities for patients to access cancer therapies.

As part of the exclusive agreement, START will leverage Trialing’s platform to distribute curated information on ongoing early-phase oncology trials throughout Europe.

This approach includes sharing real-time updates and notifying medical oncologists when new patient enrolment slots are available.

Trialing utilises its technology and structured clinical decision pathways to connect patients, physicians, and the pharmaceutical industry within a single solution.

The platform is designed to enable rapid study identification based on accurate data while supporting an agile approach led by their internal medical team.

START continues to develop its network of European clinical trial sites, focusing on accelerating early-phase oncology research while maintaining relationships with referring physicians.

The partnership aims to support improved communication, transparency and referral pathways for innovative cancer studies.

It will allow START to provide dynamic study updates via Trialing’s platform, ensuring physicians have current information on criteria related to eligibility and enrolment status.

START chairman and CEO Nick Slack said: “Access remains one of the greatest barriers in oncology clinical research. Partnering with Trialing allows us to engage physicians on a platform they already know and trust, provide clear and timely visibility into our hundreds of active trials, and make it easier to connect patients with START’s clinical trial sites across Europe.

“By reducing friction in the referral process and increasing physician awareness of START, we advance our mission of delivering hope through access.”

In October 2024, START signed a strategic collaboration with the Spanish Fundación Rioja Salud foundation to expand access to early-phase cancer clinical trials in La Rioja.